Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27764275 | 0.83 | ALDH1A1 (0.35) | ALDH1A1NPSR1CYP11B1CYP11B2TDP1 | |
| SCHEMBL24610550 | 0.80 | CPB2 (0.31) | TDP1 | |
| SCHEMBL2716190 | 0.80 | CYP11B1 (0.51) | ALDH1A1CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL487536 | 0.80 | CHRNB2 (0.36) | CYP11B1CYP11B2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1141323 | 0.79 | ALDH1A1 (0.42) | ALDH1A1NPSR1CYP11B1CYP11B2TDP1 | |
| SCHEMBL30833526 | 0.79 | ALDH1A1 (0.42) | ALDH1A1NPSR1CYP11B1CYP11B2TDP1 | |
| SCHEMBL29596980 | 0.78 | TLR7 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL15164059 | 0.78 | CHRNB2 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL487408 | 0.78 | TLR7 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL487331 | 0.78 | CYP11B1 (0.33) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049488-B1 | N'-CYANO-N-ALKYL HALIDE IMIDE AMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2015-12-09 | — | — | EP | disclosed |
| EP-2004636-B1 | Substituted enaminocarbonyl compounds used as insecticides | BAYER IP GMBH (DE) | 2015-04-22 | — | — | EP | disclosed |
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | disclosed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-20040082785-A1 | Process for making an aldehyde | WYETH | 2004-04-29 | — | — | US | disclosed |
| WO-2004006677-A1 | MALONONITRILE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-01-22 | — | — | WO | disclosed |
| US-6635771-B2 | Useful as intermediates in the synthesis of compounds having activity as chemical inhibitors of various phospholipase enzymes, particularly phospholipase A2 | WYETH | 2003-10-21 | — | — | US | disclosed |
| US-20030166649-A1 | Methods for treating arthritic disorders | WYETH | 2003-09-04 | — | — | US | disclosed |
| US-20030158405-A1 | Chemical intermediates for making a phospholipase enzyme inhibitors | WYETH | 2003-08-21 | — | — | US | disclosed |
| US-20030149029-A1 | Methods for treating asthmatic conditions | WYETH | 2003-08-07 | — | — | US | disclosed |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH | 2003-07-31 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1150952-A1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046196-A1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158405-A1 | Chemical intermediates for making a phospholipase enzyme inhibitors | PLA2R1, PLD1, PLA2G1B | ALDH1A1 984/4885NPSR1 722/4885CYP11B1 395/4885 |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TRPV1, TRPV3, TRPA1 | ALDH1A1 3932/4885NPSR1 329/4885CYP11B1 1558/4885 |
| US-20030166649-A1 | Methods for treating arthritic disorders | PLA2G12A, PLA2G4A, PLA2G4B | ALDH1A1 304/4885NPSR1 655/4885CYP11B1 760/4885 |
| US-20030149029-A1 | Methods for treating asthmatic conditions | PLA2G4A, PLA2G4B, PLA2G1B | ALDH1A1 536/4885NPSR1 768/4885CYP11B1 236/4885 |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G4C | ALDH1A1 1910/4885NPSR1 840/4885CYP11B1 1443/4885 |
| US-20040082785-A1 | Process for making an aldehyde | ALDH7A1, ALDH2, ALDH18A1 | ALDH1A1 6/4885NPSR1 3116/4885CYP11B1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.